What it sells
We build better immunotherapies
Business model breakdown
Workflow: what inputs become what output?
Cis-targeted molecule engages an immunomodulatory receptor and a target on the same immune cell, so IL-2 activates only CD8+ effector T cells; being tested in Phase 1a/1b trial.
Economics: what it saves and how it charges
UnverifiedPre-revenue therapeutics; value comes from clinical milestones, partnerships and licensing (e.g. clinical trial collaboration and supply agreement announced Jan 2025).
Distribution: how it reaches customers
UnverifiedNot sold; drug candidates advanced through clinical trials and pharma collaborations.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2019 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.